lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Sarah Jane Cressall. Founder and Chief Executive Officer, The Creation Station. For services to Creativity in Education, Entertainment and Business. Thomas Daniel Critchley. Data Scientist, Prime Minister's Office. For services to Evidence-Based Policy. Dr. Ruth Louise Cromie. Research Fellow, Wildfowl and Wetlands Trust. For services to Wetland and Waterbird Conservation. Professor Adrian Michael Cruise. Emeritus Professor, University of Birmingham. For services to Space Science. Dr. Robert Nicholas Cullinan. Director, National Portrait Gallery. For services to Art. Laurence Alexander Cummings. Conductor, Harpsichordist, Music Director of the Academy of Ancient Music and the London Handel Festival, and William Crotch Professor of Historical Performance, Royal Academy of Music. For services to Music. Lynn Cummings, JP. Commercial Category Lead, Department for Work and Pensions. For Public Service. Professor William Cushley. Chair, Expert Committee on Pesticides. For services to the Regulation of Plant Protection Products. Dr. Dipankar Dutta. Chair, South Asia Voluntary Enterprise. For services to Charity. Roy Henry Dennis, MBE. Wildlife Conservationist. For services to Wildlife. Paul Anthony Denton. For services to Charity. Dr. Darrell Carmel De Souza. Lately Principal and Chief Executive Officer, Harrow College and Uxbridge College. For services to Further Education. Morag Deyes, MBE. Artistic Director, Dance Base, Edinburgh. For services to Dance. Angela Jane Charlotte Dickson, MBE. Co-Founder, The Brain Tumour Charity. For services to People with Brain Tumours.
=== Indirect size measurement of intact complexes === Sedimentation-velocity analytical ultracentrifugation (measures the translational diffusion constant) Dynamic light scattering (measures the translational diffusion constant) Pulsed-gradient protein nuclear magnetic resonance (measures the translational diffusion constant) Fluorescence polarization (measures the rotational diffusion constant) Dielectric relaxation (measures the rotational diffusion constant) Dual polarisation interferometry (measures the size and the density of the complex) Methods that measure the mass or volume under unfolding conditions (such as MALDI-TOF mass spectrometry and SDS-PAGE) are generally not useful, since non-native conditions usually cause the complex to dissociate into monomers. However, these may sometimes be applicable; for example, the experimenter may apply SDS-PAGE after first treating the intact complex with chemical cross-link reagents.
Those who have used topical corticosteroids over a prolonged period of time Those who have used corticosteroids to cover a large surface area Those with broken skin barrier or extensive abrasions Those who have recently undergone stress (such as illness, trauma, surgery) Children under the age of 12 HPA axis suppression is preventable by supplementation with glucocorticosteroids. If HPA axis suppression occurs, it is often reversed shortly after discontinuation of treatment.
=== December === 4 December – Michael O'Neill, musician (Screaming Meemees) (born 1963). 6 December Ken Hyde, marketing academic (Auckland University of Technology) (born 1959). Bill Sutton, politician and biochemist (DSIR), MP for Hawkes Bay (1984–1990), Hawke's Bay Regional Councillor (1992–1995) (born 1944). 8 December – Murray Jones, mountaineer (born 1945). 9 December – Ross Morrison, cricketer (Auckland) and tennis administrator (born 1937). 10 December Stuart Davis, horticulturist (born 1959). Bob Manthei, educationist (University of Canterbury) and basketball commentator (born 1946). 11 December – Brent McLachlan, rock drummer (Bailter Space) and music producer (born 1961). 12 December Kelvin Lloyd, ecologist, Loder Cup (2025) (born 1968). Marilyn Yeoman, school principal and community volunteer (Hamilton Gardens), president of the New Zealand Principals' Federation (1995–1997) (born 1942). 13 December – Garry Smith, rugby league player (West Coast, Wellington, national team) (born 1941). 16 December – Alan Marley, association footballer (Dover, New Brighton, national team) (born 1951). 17 December – Peter Arnett, journalist (The Southland Times, Associated Press, CNN), Pulitzer Prize (1966) (born 1934). 21 December – John Lee, businessman and tourism pioneer (Cardrona Alpine Resort, Snow Farm, Southern Hemisphere Proving Grounds) (born 1936). 23 December – Robert Smellie, lawyer and judge, King's Counsel (since 1979), High Court judge (1985–1998) (born 1930).
Sources: en.wikipedia.org
== Radiation protection in radiotherapy == In radiotherapy, radiation protection is often overlooked in favor of structural safeguards and therapist protection. The benefit/risk assessment should prioritize both the therapeutic goal of treating the patient's cancer and the safety of all involved. However, it is crucial to ensure that radiation is delivered only where it is needed through appropriate treatment planning. By employing strong radiation protection measures, we can confidently provide effective treatment while minimizing potential risks. Linear accelerators replaced cobalt and caesium emitters in routine therapy due to their superior technical characteristics and risk profile. They have been available since about 1970. The presence of a medical physicist responsible for technical quality control is required for linear accelerators, unlike X-rays and telecurie systems. It is important to note that radiation necrosis is the necrosis of cells in an organism caused by the effects of ionizing radiation. Radionecrosis is a serious complication of radiosurgical treatment that becomes clinically apparent months or years after irradiation. Radiation therapy has significantly reduced the incidence of radionecrosis since its early days. Modern radiation techniques prioritize the sparing of healthy tissue while irradiating as much of the area around the tumor as possible to prevent recurrence. It is important to note that patients undergoing radiotherapy face a certain level of radiation risk.
=== Relation to the Avogadro constant === The number of entities (symbol N) in a one-mole sample equals the Avogadro number (symbol N0), a dimensionless quantity. The Avogadro constant (symbol NA) is given by the Avogadro number multiplied by the unit reciprocal mole (mol−1), i.e. NA = N0/mol. The ratio n = N/NA is a measure of the amount of substance (with the unit mole). The Avogadro constant was determined by a measurement of the number of 28Si atoms in a single crystalline sample.
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-{\frac {\beta IS}{N}},\\[6pt]&{\frac {dI}{dt}}={\frac {\beta IS}{N}}-\gamma I-\mu I,\\[6pt]&{\frac {dR}{dt}}=\gamma I,\\[6pt]&{\frac {dD}{dt}}=\mu I,\end{aligned}}}
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.